Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WP1220 · 1 trial · 1 indication
Safety will be evaluated by reported adverse events
| Arm | Type | Description |
|---|---|---|
| 10% WP1220 ointment | EXPERIMENTAL | 10% WP1220 ointment topically applied 2x day for 84 days |
| Name | Type | Description |
|---|---|---|
| WP1220 | DRUG | Topical administration 2x daily for 84 consecutive days |
Inclusion Criteria: 1. Age ≥ 18 years at the time of signing informed consent. 2. Clinical diagnosis of MF. 3. Stage IA, IB, IIA, IIB, or II MF: T1-T4 with measurable lesions 4. Previously treatment with at least one standard therapy used to treat Stage IA, IB, IIA, IIB, or III MF. 5. Measurable sk...
WP1220 is an investigational small molecule being studied for the treatment of cutaneous T-cell lymphoma and mycosis fungoides, a type of skin lymphoma. It is intended for adult patients with these conditions. The drug is in early clinical development and is not yet approved for commercial use.
WP1220 is being developed by Moleculin Biotech, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol MBRX. Moleculin is conducting clinical research to evaluate the safety and efficacy of WP1220 in patients with cutaneous T-cell lymphoma.
WP1220 is in Phase 1 clinical development. It has completed a Phase 1 trial, which was an uncontrolled, open-label study. The drug is still investigational and has not received regulatory approval. Further clinical studies would be needed to assess its safety and effectiveness in larger patient populations.
WP1220 has been studied in one clinical trial with the identifier NCT04702503. This was a Phase 1 study titled 'Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)'. The trial was completed and enrolled 5 participants in Poland.
WP1220 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not been evaluated in later-stage trials. Regulatory approval would require additional studies demonstrating safety and efficacy.